AIP
TLIS

Ameritas Investment Partners’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Ameritas Investment Partners’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-72
Closed -$2K – 3282
2022
Q1 		$2K Hold
72
– – ﹤0.01% 3054
2021
Q4 		$4K Hold
72
– – ﹤0.01% 3068
2021
Q3 		$7K Hold
72
– – ﹤0.01% 3011
2021
Q2 		$12K Hold
72
– – ﹤0.01% 2905
2021
Q1 		$14K Buy
+72
New +$18K ﹤0.01% 2726

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameritas Investment Partners's TLIS Position: Q2 2022 in Review

Ameritas Investment Partners sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q2 2022, closing a stake of 72 shares — an estimated $2K sold.

Ameritas Investment Partners first reported a position in TLIS in Q1 2021 and held it in 5 quarters. The position peaked at $14K in Q1 2021. 35 funds tracked by Wall St. Rank hold TLIS as of Q2 2022.

  • Ameritas Investment Partners reported no remaining Talis Biomedical Corporation Common Stock position as of Q2 2022 after selling out during the quarter.
  • Ameritas Investment Partners sold 72 Talis Biomedical Corporation Common Stock shares in Q2 2022, an estimated $2K.
  • Ameritas Investment Partners first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 5 quarters.
  • Ameritas Investment Partners's Talis Biomedical Corporation Common Stock position peaked at $14K in Q1 2021.
  • 35 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.